Direkt zum Inhalt
Merck

B8437

Sigma-Aldrich

Anti-Biliverdin Reductase A antibody produced in rabbit

IgG fraction of antiserum, buffered aqueous solution

Synonym(e):

Anti-BLVR, Anti-BLVRA, Anti-BVR, Anti-BVRA

Anmeldenzur Ansicht organisationsspezifischer und vertraglich vereinbarter Preise


About This Item

UNSPSC-Code:
12352203
NACRES:
NA.41

Biologische Quelle

rabbit

Konjugat

unconjugated

Antikörperform

IgG fraction of antiserum

Antikörper-Produkttyp

primary antibodies

Klon

polyclonal

Form

buffered aqueous solution

Mol-Gew.

antigen ~35 kDa

Speziesreaktivität

human

Methode(n)

immunoprecipitation (IP): 5-10 μL using human HeLa cell lysates
western blot: 1:250-1:500 using whole extracts of human HepG2 cells

UniProt-Hinterlegungsnummer

Versandbedingung

dry ice

Lagertemp.

−20°C

Posttranslationale Modifikation Target

unmodified

Angaben zum Gen

human ... BLVRA(644)

Verwandte Kategorien

Allgemeine Beschreibung

Biliverdin reductase A (BVRA) contains a domain that acts as a serine/ threonine/ tyrosine kinase and belongs to the insulin receptor substrate family. Whereas most tyrosine kinase activity is membrane-bound, BVR is a soluble protein. BVRA gene is mapped to human chromosome 7p13.

Spezifität

Anti-Biliverdin Reductase A recognizes human Biliverdin Reductase A.

Immunogen

human biliverdin reductase A recombinant protein.

Anwendung

Anti-Biliverdin Reductase A antibody produced in rabbit may be used in western blotting and immunoprecipitation.

Biochem./physiol. Wirkung

Biliverdin reductase A (BVR, BLVRA) catalyzes the conversion of biliverdin to bilirubin in the presence of nicotinamide adenine dinucleotide phosphate (NADPH) or nicotinamide adenine dinucleotide (NADH). Biliverdin reductase A is also considered as a major physiologic cytoprotectant and may have other protective properties in disease states. It has been shown to suppress experimental autoimmune encephalomyelitis in rats. The depletion of the enzyme leads to the accumulation of cellular oxidants and augmented cell death. Mutation in the BVRA gene is implicated in hyperbiliverdinaemia or green jaundice.

Physikalische Form

Solution in 0.01 M phosphate buffered saline, pH 7.4, containing 15 mM sodium azide.

Lagerung und Haltbarkeit

Store at -20 °C. For continuous use, the product may be stored at 2-8 °C for up to one month.For extended storage, freeze at -20 °C in working aliquots. Repeated freezing and thawing, or storage in “frost-free” freezers, is not recommended. If slight turbidity occurs upon prolonged storage, clarify the solution bycentrifugation before use. Working dilution samples should be discard if not used within 12 hours.

Haftungsausschluss

Unless otherwise stated in our catalog, our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Sie haben nicht das passende Produkt gefunden?  

Probieren Sie unser Produkt-Auswahlhilfe. aus.

Lagerklassenschlüssel

10 - Combustible liquids

Flammpunkt (°F)

Not applicable

Flammpunkt (°C)

Not applicable


Analysenzertifikate (COA)

Suchen Sie nach Analysenzertifikate (COA), indem Sie die Lot-/Chargennummer des Produkts eingeben. Lot- und Chargennummern sind auf dem Produktetikett hinter den Wörtern ‘Lot’ oder ‘Batch’ (Lot oder Charge) zu finden.

Besitzen Sie dieses Produkt bereits?

In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.

Die Dokumentenbibliothek aufrufen

Mats Gåfvels et al.
Liver international : official journal of the International Association for the Study of the Liver, 29(7), 1116-1124 (2009-07-08)
Hyperbiliverdinaemia is a poorly defined clinical sign that has been infrequently reported in cases of liver cirrhosis or liver carcinoma, usually indicating a poor long-term prognosis. To clarify the pathogenesis of hyperbiliverdinaemia in an extended case report. A 64-year-old man
Flavia Agata Cimini et al.
Biochimica et biophysica acta. Molecular basis of disease, 1865(6), 1490-1501 (2019-03-04)
Biliverdin reductase-A (BVR-A) is a serine/threonine/tyrosine kinase involved in the regulation of insulin signaling. In vitro studies have demonstrated that BVR-A is a substrate of the insulin receptor and regulates IRS1 by avoiding its aberrant activation, and in animal model
Urszula M Florczyk et al.
Pharmacological reports : PR, 60(1), 38-48 (2008-02-16)
Biliverdin reductase (BVR) was known for a long time solely as an enzyme converting biliverdin to bilirubin, the major physiological antioxidant. Recent years revealed unique features of this protein which are not related to its reductase activity. The most intriguing
Nidhi Sharma et al.
Neurobiology of disease, 125, 176-189 (2019-02-10)
Hyper-active GSK-3β favors Tau phosphorylation during the progression of Alzheimer's disease (AD). Akt is one of the main kinases inhibiting GSK-3β and its activation occurs in response to neurotoxic stimuli including, i.e., oxidative stress. Biliverdin reductase-A (BVR-A) is a scaffold
Damian Klóska et al.
Archives of biochemistry and biophysics, 678, 108182-108182 (2019-11-11)
Endothelial dysfunction accompanied by the loss of endothelial cell phenotype plays an essential role in cardiovascular diseases. Here, we report that knockdown of biliverdin reductase (BVR), the enzyme of the heme degradation pathway converting biliverdin to bilirubin, shifts endothelial phenotype

Unser Team von Wissenschaftlern verfügt über Erfahrung in allen Forschungsbereichen einschließlich Life Science, Materialwissenschaften, chemischer Synthese, Chromatographie, Analytik und vielen mehr..

Setzen Sie sich mit dem technischen Dienst in Verbindung.